Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer

Abstract

Introduction: Patients have reported late effects and symptom-related bother following postoperative radiotherapy for prostate cancer. Methods:Patients treated with postoperative radiotherapy were surveyed at a median 56 months after radiotherapy using the Prostate Cancer Radiation Therapy instrument. A retrospective review was undertaken to obtain Radiation Therapy Oncology Group-Late Effects Normal Tissue (RTOG-LENT) toxicity scores at baseline and during follow-up.

Radiotherapy in the Management of Prostate Cancer After Radical Prostatectomy

“…The promising bNED results (67% at 4 years) await confirmation through longer follow-up. [91] A retrospective analysis of 196 patients could show that bladder filling checks and image guidance can limit acute grade 3 GU toxicity after high-dose (76 Gy) IMRT to as low as 1-3%; [92] grade 3 GI tract events were not observed in this study. Where reported, sexual function was frequently and severely impaired (range: 25-88%), [89,[93][94][95] while the contribution of RT to this problem is low compared with the impact of surgery alone; [94] in SWOG trial patients, the offset was less than 10% above the approximately 85% post-RP level with a slight recovery over 5 years in both therapy arms (the updated European Association of Urology guideline lists post-RP impotence as the most frequent side effect at 25-100%).…”

Posterior Reconstruction and Outcomes of Laparoscopic Radical Prostatectomy in a High-Risk Setting

“…Furthermore, a large number of patients in the study group underwent adjuvant radiotherapy, which adversely affects early and late urinary continence ( Figure 8 ) . 22 …”

Urethrokrurale Fistel zum Adduktorenkanal

“…Sie kön-nen den Darm und dessen Funktion betreffen [1,2], aber auch zu Einschränkun-gen der Blasenfunktion oder zu einer Verschlechterung der Erektionsfähigkeit und Kontinenzsituation führen [3]. Urinfisteln nach Brachytherapie der Prostata treten in 0,3-3,0% auf und nach perkutaner Bestrahlung in bis zu 0,6% [4].…”